We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genomic DNA from Fecal Specimens Helps Identify EHEC

By LabMedica International staff writers
Posted on 13 Jul 2011
High throughput pathogen examination of stool samples identifies the enterohemorrhagic Escherichia coli (EHEC) responsible for the epidemic of bloody diarrhea associated with hemolytic-uremic syndrome (HUS) that appeared in Germany.

The automated MagNA pure sample preparation system for nucleic acid isolation and LightCycler Real-Time polymerase chain reaction (PCR) instrument from Roche Applied Science (Penzberg, Germany) have been used for high throughput examination of EHEC pathogens in primary stool samples during the E.coli epidemic.

In a study carried out by Ralf Bialek [Laboratory of Dr. More...
Krause and colleagues] (MVZ GmbH; Kiel, Germany), human stool samples were processed using the high throughput MagNA Pure 96 workstation, isolating high quality total genomic DNA from primary fecal specimens. Targeting the toxin genes of EHEC by a LightCycler Real-Time PCR test demonstrated that fecal specimens could be used as starting material to detect EHEC infection in epidemic situations reducing the turnaround from at least overnight incubation to hours.

The fully automated robotic MagNA Pure 96 Instrument used in this study isolates nucleic acids from 96 samples in approximately one hour. The Roche platform is an efficient, cost-effective way to prepare template DNA from large numbers of stool samples in epidemic situations. Subsequent LightCycler 480 Real-Time PCR was found to be accurate and reproducible using proven specific, sensitive PCR primers and probes, targeting the Shiga toxin genes of EHEC, available as LightMix kit EHEC.

A new pathogen universal protocol was established using a 200 µL sample volume and 100 µL elution volume. E. coli Shiga toxin genes were amplified in the presence of two pairs of fluorescently labeled hybridization probes targeting stx-1 and stx-2, followed by LightCycler system melting curve analysis discriminating the toxin gene subtypes. The bacterial parC gene (encoding the topoisomerase IV subunit of Enterobacteriaceae) was used as an extraction control to prove presence of extracted DNA and to exclude PCR inhibitors. Systematic testing of this workflow should significantly contribute to the early detection and surveillance of future EHEC infections, as well as other emerging bacterial epidemics.

The team evaluated a novel four-color multiplex assay using hydrolysis probes for the LightCycler 480 Instrument, targeting both toxin genes (stx1 and stx2), the wzx gene (marker for the O104 serotype), and an internal control. This new assay enables the analysis of suspected samples in a single reaction, for a faster more cost-effective time-to-result, which is particular important during an outbreak, when many samples have to be studied in short time.

More than 3,400 laboratory confirmed EHEC and HUS cases have been reported, 39 of them with fatal outcome according to the Robert Koch Institute’s (Berlin, Germany) report, dated June 20, 2011. The majority of EHEC infected individuals live in Germany, but significant numbers of infections have also been reported in Sweden, Russia, as well as other European countries.

Related Links:

Roche Applied Science
Robert Koch Institute



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.